31Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Thailand
Neuroscience Intelligence
Thailand neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #47 of 50 · Data maturity A · Research score 27.0 · Data confidence 100.0 / 100 · Snapshot 2026-10-12 03:36 UTC.
9Recruiting trials
22Publications
15Institutions
Executive interpretation
Thailand ranks #47 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC75 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
UCB Pharma20 recruiting
CHIMES Society10 recruiting
IRCCS San Raffaele Roma11 recruiting
International Rescue Committee10 recruiting
Department of Medical Services Ministry of Public Health of Thailand10 recruiting
Mae Fah Luang University10 recruiting
Mahidol University10 recruiting
Khon Kaen University10 recruiting
Disease activity
Parkinsons11trials
Epilepsy6trials
Stroke5trials
Multiple Sclerosis2trials
Pain Neuropathy2trials
Anxiety1trials
Depression1trials
Research institutions
King Mongkut's University of Technology North BangkokOpenAlexlinked institution
Prince of Songkla UniversityOpenAlexlinked institution
Department of Disease ControlOpenAlexlinked institution
Thammasat UniversityOpenAlexlinked institution
Chulalongkorn UniversityOpenAlexlinked institution
King Chulalongkorn Memorial HospitalOpenAlexlinked institution
Naresuan UniversityOpenAlexlinked institution
Ramathibodi HospitalOpenAlexlinked institution
Piyavate HospitalOpenAlexlinked institution
Chiang Mai UniversityOpenAlexlinked institution
Clinical evidence trail
NCT07605507Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical CancerACTIVE_NOT_RECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)ACTIVE_NOT_RECRUITING
NCT05973773REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)ACTIVE_NOT_RECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04736706A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)ACTIVE_NOT_RECRUITING
NCT06595524Development of the Online Mindfulness-based Intervention (MFU-Mindful Application) for Thai-university StudentsCOMPLETED
NCT06201117Effects of Preparatory Information on Anxiety and Treatment Adherence in Heart Surgery PatientsUNKNOWN
Research evidence trail
PUBMEDDiagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis.2026-12-01
PUBMEDPsychological stress-associated ceramide and diacylglyceride lipotoxicity as contributors to first-episode depression pathophysiology: A neuroimmune-metabolic-oxidative stress (NIMETOX) perspective.2026-12-01
PUBMEDLong-term causes of death in 888,003 ischemic stroke patients in Thailand: a nationwide retrospective study with 18-year follow-up.2026-12-01
PUBMEDUnderrecognized restless legs syndrome in Parkinson's disease: Diagnostic delay, association with sleep burden, and dopaminergic exposure in a Thai cohort.2026-12-01
PUBMEDSleep-timing mismatch (MSFsc-lights-off interval) and its association with polysomnographic sleep parameters in a clinical population under a fixed laboratory schedule.2026-11-01
PUBMEDPrevalence and impact of cerebral small vessel lesions in mild cognitive impairment and mild dementia due to Alzheimer's disease patients in memory clinic: Preparation for anti-amyloid therapy in Thailand.2026-10-10
PUBMEDPsychiatric and medical comorbidities in patients with migraine before and during the COVID-19 pandemic in Thailand: a retrospective comparative cohort study of two different clinical groups.2026-10-01
PUBMEDReal-World Functional Gains in Thai Children With Attention-Deficit/Hyperactivity Disorder: A 24-Month Naturalistic Study.2026-10-01
PUBMEDWhen machines see more: Digital technologies, measurement, and meaning in hyperkinetic movement disorders.2026-09-02
PUBMEDOptimizing Multidisciplinary Neurotraumatology Education in Thailand: Aptitude-Dependent Outcomes in Virtual Patient Simulation in Collaboration with the Academy for Multidisciplinary Neurotraumatology.2026-09-01
PUBMEDClinical Factors and Comorbidities Associated With Uncontrolled Seizures in Children With Epilepsy: A Nationwide Study.2026-09-01
PUBMEDThe role of psychological resilience in the relationship between complex post-traumatic stress disorder symptom severity and functioning impairment in mental health support-seeking Australian defence force veterans: A cross-sectional study.2026-09-01
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.